• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

P.T. Jyothi Datta

Mumbai, Oct. 1 All decks seem to have been finally cleared for the review of the rejection of Novartis’ patent on its cancer drug Glivec. The Supreme Court has appointed Dr P.C. Chakraborty, of the Patent Office in Kolkata, as technical member on the Intellectual Property Appellate Board (IPAB) for the review of this case.

The appointment of the IPAB’s technical member had itself become a point of litigation between Novartis and Natco (also party to the case), side-tracking the actual review of the rejected Glivec patent.

The reason for Novartis’ concern was that the earlier technical member appointed to the IPAB, Mr S. Chandrasekaran, was the former Patent Controller under whom Novartis’ patent on Glivec had been rejected in the first place, in January 2006.

The new technical member Dr Chakraborty is Deputy Controller of Patents and Designs at the Kolkata Patent Office, and his name was selected from a list of 20 patent attorneys and 22 patent controllers that the Centre submitted to the apex court, a legal source handling the case told Business Line.

The court has also directed the IPAB to hear the issue on November 3, to decide other modalities of the case.

More Stories on : Pharmaceuticals | IPR | Courts/Legal Issues

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line